Pharming, Aslan Group sign lactoferrin deal
This article was originally published in The Tan Sheet
Executive Summary
The Netherlands-based biotech firm Pharming Group licenses Istanbul, Turkey-based Aslan to develop, manufacture and market Pharming's human lactoferrin product, which is in "late stage development" for use in food products, Pharming says Nov. 18. Pharming breeds "experimental herds" of cows to produce milk with human lactoferrin, a protein in mammals. Under the 10-year agreement, Aslan will pay sales royalties to Pharming while it has exclusive marketing rights to produce hLF with Pharming's technology and sells food and supplements with the ingredient in Turkey, the Middle East, Russia and other areas. Aslan will pay 20 million euros ($25.2 milliion dollars under Nov. 18 conversion rates) in licensing fees in the next three years